Abstract The 2026 proposal to stage type 2 diabetes by β-cell trajectory and continuous glucose monitoring (CGM) metrics—specifically time in tight range (TITR)—represents a pivotal advance in dysglycaemia phenotyping. Yet, this innovation exposes a critical translational void: actionable algorithms to convert granular CGM outputs into stage-specific, stability-oriented therapeutic responses remain absent from clinical guidelines.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Bowu
Contact Bowu, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack